Title : Impaired insulin secretion in human diabetes mellitus. II. A possible role for prostaglandins.

Pub. Date : 1981 Jan

PMID : 6784135






9 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In search of possible endogenous factors which impair insulin release, we have investigated the effect of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin (PGs) synthesis, upon insulin responses to glucose and arginine in subjects with type II (adult-on-set) diabetes mellitus. acetylsalicylic acid lysinate insulin Homo sapiens
2 In search of possible endogenous factors which impair insulin release, we have investigated the effect of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin (PGs) synthesis, upon insulin responses to glucose and arginine in subjects with type II (adult-on-set) diabetes mellitus. acetylsalicylic acid lysinate insulin Homo sapiens
3 Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). acetylsalicylic acid lysinate insulin Homo sapiens
4 Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). acetylsalicylic acid lysinate insulin Homo sapiens
5 Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). acetylsalicylic acid lysinate insulin Homo sapiens
6 Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). acetylsalicylic acid lysinate insulin Homo sapiens
7 Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). acetylsalicylic acid lysinate insulin Homo sapiens
8 Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). acetylsalicylic acid lysinate insulin Homo sapiens
9 Acute insulin response to arginine (5 g iv) was also increased by LAS infusion. acetylsalicylic acid lysinate insulin Homo sapiens